ライフサイエンスコーパス: stool

1 hich were below the noninferiority margin (2 stools).

2 resulting in continuous leakage of urine or stool.

3 in urine and A. lumbricoides DNA detected in stool.

4 ondiagnostic examinations from poorly tagged stool.

5 Neu5Gc levels and Bacteroides spp. in infant stool.

6 oped eosinophilia without diarrhea or bloody stool.

7 sequence changes from the original virus in stool.

8 tin and anti-toxin B Ig A/G were measured in stool.

9 t loss, and 5% had intermittent bloody loose stool.

10 olely based on the detection of worm eggs in stool.

11 wabs and viral shedding in blood, urine, and stool.

12 r compared with 5% of patients given placebo stool.

13 ection of Clostridioides difficile toxins in stool.

14 positively correlated between breastmilk and stool.

15 and spread systemically prior to shedding in stool.

16 omposition in healthy participants in frozen stools.

17 associated with vomiting and frequent loose stools.

18 had abdominal pain, 24% had nonbloody loose stool, 18% had vomiting, 18% had weight loss, and 5% had

19 ted odds ratio for the detection of virus in stools, 2.04; 95% confidence interval, 1.06-3.91) and HR

20 Virus was detectable in the stool (4/8 [50%]) and blood (1/12 [8%]) by PCR but not i

21 Twenty patients had diarrhea, 8 bloody stools, 4 fever, and 1 hypothermia.

22 We sequenced 1,560 isolates (1,001 stool, 559 environment) and focused our genomic analyses

23 antly higher proportion of women given donor stool (69%) had a response than men (29%) (P = .01).

24 ir most predominant feature was bloody loose stool (78%).

25 ter vision as a uroflowmeter, and classifies stool according to the Bristol stool form scale using de

26 ER-287 engraftment (dose species detected in stool after but not before SER-287 administration).

27 In this prospective study, a total of 226 stool and 178 plasma samples were received from patients

28 Of 172 human NTS isolates, 90 (52.3%) from stool and 82 (47.7%) from blood, 53 (30.8%) were Salmone

29 Stool and blood samples were collected at baseline and e

30 nge study to investigate virus recovery from stool and emesis samples using HBGA-coated beads.

31 s surveillance involves virus isolation from stool and environmental samples, intratypic differential

32 and real-time sequencing of polioviruses in stool and environmental samples.

33 detection and sequencing of polioviruses in stool and environmental samples.

34 e collected and used to prepare matched bulk stool and FecalSwab samples.

35 as, while Desulfovibrio was enriched both in stool and in mucosal biopsies.

36 ating equivalent performance to matched bulk stool and maintaining molecular detection sensitivity wh

37 Weekly stool and nasal swabs and daily symptom diaries were col

38 1423 of 11 124 (12.8%) and 17 of 8100 (0.2%) stool and nasal swabs, respectively.

39 biome with chronic GVHD (cGVHD) by analyzing stool and plasma samples collected late after allo-HCT u

40 wo separate ScheBo-Biotech-AG ELISA kits for stool and plasma samples.

41 hain reaction (PCR) performed on an unformed stool and received vancomycin within 2 days of testing.

42 tion between sulfur-metabolizing bacteria in stool and risk of CRC over 26 years of follow-up.

43 coated bacteria (IgA-Biome) was conducted on stool and saliva samples of normoglycemic participants a

44 Biome alpha diversity were apparent for both stool and saliva, while overarching bacterial community

45 ifferential effects of diet on each taxon in stool and small-intestine mucosa samples.

46 ociated with sulfur-metabolizing bacteria in stool and then investigated its association with risk of

47 In stool and tongue samples, microbes shared between mother

48 RNA gene amplicon sequencing of longitudinal stool and tongue swab samples.

49 the presence of the enterococcal prophage in stools and expression of a TMP-cross-reactive antigen by

50 co-occur in mothers' milk and their infants' stool, and co-occurrence is reduced when infants receive

51 We tested patient sera, stool, and gastric aspirates using mouse bioassay for Bo

52 nced reinfection as determined by HEV RNA in stool, and increase in IgG anti-HEV levels between 63- a

53 ain reaction was negative in nasopharyngeal, stool, and respiratory samples and was positive on serol

54 nts will have nasopharyngeal, blood, buccal, stool, and urine samples collected, plus complete a ques

55 of daily bowel movements, consistency of the stools, and abdominal circumference were also recorded.

56 ons of lowered sIgA concentrations in infant stool are altered microbe-sIgA interactions, greater ris

57 ration of more than 5 days and the number of stools (assessed in a noninferiority analysis) and the o

58 ecular screening for Blastocystis sp. at our stool bank identified 2 donors with prior negative micro

59 CDI and 249 (96%) used an unknown donor (eg, stool bank).

60 ogical measures of transmission aligned with stool-based measures of infection (rho = 0.94), and sero

61 to S. mansoni soluble egg antigen (SEA) with stool-based measures of infection among 3,663 preschool-

62 Furthermore, stool bile acids and propionate are elevated, especially

63 tum, nasopharyngeal or oropharyngeal, urine, stool, blood and environmental specimens.

64 ngdom, in 2015 to isolate K. pneumoniae from stool, blood, and the environment.

65 R may not only detect nonviable organisms in stool but also viable organisms that remain undetectable

66 f patients with an initial response to donor stool but not in patients with a prior nonresponse.

67 ng this early pre-habilitation (ie, 3 days), stool butyrate per microbial biomass remained low and po

68 ours before stool collection) and a positive stool C. difficile nucleic acid amplification test were

69 Greater stool calorie loss was observed during underfeeding rela

70 In each, stool calorie loss, a direct proxy of nutrient absorptio

71 both interventions that resulted in greater stool calorie loss.

72 dietary and pharmacological intervention on stool calorie loss.

73 We hypothesized that stool calories expressed as percentage of caloric intake

74 ater number of dose species were detected in stool collected on day 10 and all subsequent time points

75 In conclusion, the use of GutAlive for stool collection and transport optimized the viability a

76 This study utilized a well-defined stool collection from a GII.2 Snow Mountain Virus (SMV)

77 in any 24-hour period in the 48 hours before stool collection) and a positive stool C. difficile nucl

78 Fresh stool collections were flash frozen from 236 infants at

79 Plasma and stool concentrations of fidaxomicin and its active metab

80 of fidaxomicin and OP-1118 was minimal, and stool concentrations were high.

81 Reported changes in stool consistency(3) and inflammation status(4) during t

82 sp., a commensal gut protozoan, followed by stool consistency, were major determinants of the gut mi

83 subject-specific and weakly correlated with stool consistency.

84 vestigated by measuring body weight changes, stool consistency/bleeding and colon length.

85 A subset of Clostridiaceae were depleted in stool corresponding with baseline adenomas, while Desulf

86 Rates of reproducibility in stool culture for these pathogens ranged from 56.3 to 77

87 including some not detected by conventional stool culture.

88 ildren were found to be infected with NTS by stool culture.

89 Our center replaced stool cultures and other conventional microbiologic meth

90 nd compared the results to those of standard stool cultures.

91 Moreover, studies often analyze only stool, despite microbial diversity differing substantial

92 BackgroundMultitarget stool DNA (mt-sDNA) screening has increased rapidly sinc

93 m absolute quantification of host DNA in 200 stool DNA extracts from samples that were serially colle

94 ening were greater than those of multitarget stool DNA.

95 tridioides difficile toxin concentrations in stool do not differentiate between C. difficile infectio

96 lin A or serum neutralizing antibody) and/or stool excretion of the vaccine strain, stratified by HBG

97 erformance was equivalent (P > 0.48) to bulk stool for all targets when 50 mul of FecalSwab specimen

98 Furthermore, screening the FMT donor stool for antibiotic resistance revealed 21 populations

99 , Italy) is a convenient alternative to bulk stool for the diagnosis of enteric pathogens.

100 g abdominal pain associated with a change in stool form or frequency.

101 dominal pain, IBS symptom frequency, Bristol Stool Form Scale and quality of life.

102 nd classifies stool according to the Bristol stool form scale using deep learning, with performance t

103 n score after FMT, 3.1; range, 951.29-5.90), stool frequency (mean reduction, 13%; median score befor

104 ymptom resolution (UC: rectal bleeding [RB], stool frequency [SF]; CD: abdominal pain [AP], liquid st

105 nts with modified Mayo Clinic scores (MCSs) (stool frequency, rectal bleeding, and endoscopy findings

106 blockage are just as important as decreased stool frequency.

107 methods would behave with an actual sample, stool from a donor was spiked with cells from the same c

108 Additional GF mice were colonized with stool from controls (Ctrl-Hum) and patients with cirrhos

109 metagenomic, and transcriptomic profiling of stool from ileal pouches (surgically created resevoirs)

110 Stool from mice given ampicillin had altered composition

111 We tested stools from enrolled participants and non-diarrheal cont

112 Stools from learned helpless, non-learned helpless, and

113 Stools from patients with HE cirrhosis after antibiotics

114 Stools from the same patients 15 days after FMT from a h

115 Patients given donor stool had significant improvements in level of discomfor

116 lammation and has a high prevalence in loose stools in humans(1,2).

117 distention associated with nausea and liquid stools; in addition, she had an 8-month small and medium

118 A 10% increase in the proportion of stools infected was associated with mean reductions of 0

119 In contrast, 96% of C. difficile stool isolates were toxin-encoding.

120 quency [SF]; CD: abdominal pain [AP], liquid stools [LS]) and outcome duration.

121 Moreover, stool markers may define the readiness of the microbiome

122 ts for greater than 4 weeks, suggesting that stool may hold utility as an additional source for diagn

123 sIgA was quantified in infant stool (mean age 3.7 months) with Immundiagnostik ELISA.

124 ohort of 307 healthy men, we profiled serial stool metagenomes and metatranscriptomes and assessed di

125 ti-study, integrative analysis on 4347 human stool metagenomes from 34 published studies across healt

126 We obtained stool metagenomes from CD patients in remission and asse

127 s of 788 oral cavities worldwide with paired stool metagenomes.

128 Using deep shotgun stool metagenomics analysis, we found a rapid increase i

129 A classifier leveraging stool metatranscriptomes resulted in modest power to pre

130 differences in both innate immunity and the stool microbiome in a biogeographical population-specifi

131 his, we compared the innate response and the stool microbiome of 2-y-old HEU and HUU children from Be

132 RNA gene sequencing; 122 patients had paired stool microbiome profiles at both day 1 and week 12.

133 distinct from nearby sites and unrelated to stool microbiome with more Actinobacteria, Fusobacteria

134 thesized, population-specific differences in stool microbiomes were readily detected and included red

135 s directly correlate to differences in their stool microbiomes.

136 safety, tolerability, and impact on mucosal/stool microbiota and brain function in HE after capsular

137 lated with oral microbes) is associated with stool microbiota composition.

138 restoration of bacterial composition of the stool microbiota, transitioning from Firmicutes dominant

139 ge scale surveys of gut bacterial community, stool microRNA (miRNA) and short chain fatty acid (SCFA)

140 reatment S. stercoralis testing by serology, stool microscopy, and/or stool PCR.

141 mansoni infections have been detected using stool microscopy, which is logistically difficult at pro

142 ation of donor stools (n = 43) or autologous stools (n = 19) in a double-blind study, performed from

143 Patient stools (n = 376) and environmental swabs (n = 922) were

144 gle-dose nasojejunal administration of donor stools (n = 43) or autologous stools (n = 19) in a doubl

145 Carrier-NAAT patients had positive stool NAAT but no diarrhea.

146 Stool, nasal and skin samples of 6-month-old DIABIMMUNE

147 During the last follow-up, the stool number was the same as before CDI except for 1 pat

148 Klebsiella pneumoniae was isolated from stool of 17/149 (11%) patients and 18/922 swabs of their

149 y produced signalling lipids elevated in the stool of IBD patients and a T-cell transfer model of col

150 ed through the fecal-oral route, shed in the stool of infected individuals, and spread either by dire

151 n aggregation assay using adult patients and stool of pediatric patients with inflammatory bowel dise

152 contrast, SARS-CoV-2 can be detected in the stool of some patients for greater than 4 weeks, suggest

153 Vaccine virus was detected in the stools of 15 (100%) participants receiving vaccine candi

154 able molecular assays and support the use of stool PCR to confirm diagnosis when SARS-CoV-2 is undete

155 The two stool PCR-positive, nasopharyngeal/oropharyngeal PCR-neg

156 esting by serology, stool microscopy, and/or stool PCR.

157 ort study of 235 MSM who underwent multiplex stool polymerase chain reaction (PCR) testing between 1

158 Manual light microscopy of stool remains the gold standard but can be insensitive,

159 fter single FMT, 21% of patients given donor stool reported effects that lasted for longer than 1 yea

160 At week 12, 56% of patients given donor stool reported improvement in both primary endpoints com

161 the catalyst of choice: the resulting piano-stool ruthenium carbenes can engage a tethered alkene in

162 ichia coli isolates were collected from each stool sample (n = 21,256 total) and were subjected to br

163 Stool sample examination was performed using RT-PCR.

164 From the stool sample of five mice that were fed with (15)N hydro

165 lable, one child (<= 5 years-old) provided a stool sample.

166 We collected stool samples (n = 517) from full-term (n = 72) and pret

167 sed egg counts can vary highly over repeated stool samples and smears.

168 Patients (n = 46) collected stool samples and were grouped by use of opioid agonists

169 Stool samples and/or rectal swabs underwent molecular se

170 st-line antibiotic azithromycin, detected in stool samples by mass spectrometry.

171 and quantity for metagenomic sequencing from stool samples can be challenging.

172 We tested stool samples collected at 1, 3, 6, and 12 months of age

173 A targeted analysis revealed that in stool samples collected at the end of the study period,

174 We analyzed microbiomes of stool samples collected from 133 patients collected at t

175 We abstracted medical charts and tested stool samples for 22 pathogens via multiplex gastrointes

176 ested 3663 diarrheal and 18 148 asymptomatic stool samples for 29 enteropathogens.

177 ked rectal swabs to that of traditional bulk stool samples for enteric pathogen detection using the B

178 Stool samples from 10 people with current depressive sym

179 ing OPV vaccination and compared findings to stool samples from 16 age-matched infants in the United

180 cterial microbiome profiles of thrice-weekly stool samples from 20 intensively treated AL patients (f

181 By sequencing 497 longitudinal stool samples from 271 OPV2 recipients and household con

182 tagenomic sequencing on 3 serially collected stool samples from 30 Bangladeshi infants following OPV

183 16S ribosomal RNA analyses were performed on stool samples from 405 HIV-infected and 111 uninfected p

184 ncing data from 163 longitudinally collected stool samples from 63 HEU infants randomized to receive

185 ncing data from 163 longitudinally collected stool samples from 63 HEU infants randomized to receive

186 ers of SER-287 dose species were detected in stool samples from all SER-287 groups compared with the

187 Metagenomic and metabolomic analyses of stool samples from an 8-week inpatient study revealed ma

188 Multiple human viruses were more abundant in stool samples from babies who were exclusively fed on fo

189 rom patients receiving FMT for active UC and stool samples from donors, we associated specific bacter

190 alence from Kato Katz examinations of single stool samples from each patient was 23% versus 39% (RR 0

191 et al. (2020) sequence breastmilk and infant stool samples from mother-infant dyads to investigate th

192 of CRCs and adenomatous polyps in plasma and stool samples in an Iranian population.

193 irus alone or in mixtures when tested on 155 stool samples in Pakistan.

194 sed analysis was performed on oral swabs and stool samples obtained biweekly from baseline until neut

195 Microbial DNA in stool samples obtained from 40 subjects were characteriz

196 , miRNA, and metabolites were extracted from stool samples of 15 CD patients, eight with active disea

197 , enterotypes, and differential abundance in stool samples of 666 elderly TREND (Tubingen Evaluation

198 ber of SER-287 dose species were detected in stool samples on days 7 and 10 from subjects who receive

199 of KK-based surveys depends on the number of stool samples per person and the number of smears per sa

200 ta, publicly available data sets and patient stool samples showed that a subset of patients with C di

201 icles purified from infant meconium or early stool samples shows few or no particles, but by one mont

202 assively identified outpatient cases through stool samples submitted for clinical diagnostics.

203 as evaluated using 211 residual deidentified stool samples tested with a GDH-and-toxin EIA (C.

204 ties of high-molecular-weight DNA from human stool samples that are suitable for downstream long-read

205 Stool samples were analyzed by 16S rRNA V4 region sequen

206 Weekly stool samples were collected for 6 wk for microbiota ana

207 Stool samples were collected for microbiota amplicon seq

208 Frozen stool samples were collected from 10 healthy volunteers

209 Serial stool samples were collected from 196 children who prese

210 Stool samples were collected monthly and analyzed for HR

211 Stool samples were collected on an approximately biweekl

212 Stool samples were collected on day 1 and week 12 and pr

213 Stool samples were collected prospectively in 182 patien

214 Stool samples were collected, and microbiomes were analy

215 Stool samples were obtained from mothers and infants and

216 Stool samples were obtained from patients with chronic l

217 The stool samples were stored at -80 degrees C before being

218 NAAT-positive stool samples were tested by an ultrasensitive toxin ass

219 c discovery of three virus families in human stool samples with determination of probable hosts.

220 Of 101 patients who provided two or more stool samples, 40 (40%) developed E. faecium carriage af

221 We collected 1453 stool samples, at 5, 13, 21, and 31 weeks postpartum (in

222 l could be used to detect polyp and tumor in stool samples, respectively.

223 om VRE swabs, and from C. difficile-positive stool samples, were genome sequenced.

224 erived from the throat or lung, but not from stool samples-in spite of high concentrations of virus R

225 s subtype 4 (ST4) cysts, isolated from human stool samples.

226 ce genes, classes and mechanisms in oral and stool samples.

227 mes were also correlated with microbiomes of stool samples.

228 nd untargeted metabolomics were performed on stool samples.

229 ARG-species associations between saliva and stool samples.

230 s to analyze metagenomics data from 13 human stool samples.

231 cile was isolated from 1588 (67.2%) baseline stool samples.

232 lood, as well as IgA and IgG anti-toxin B in stool, separated CDI patients from all other groups.

233 prospective cohort study of healthy infants, stools serially collected between ages 1-2 and 9-12 mont

234 At the start of IC, higher stool Shannon diversity (hazard ratio [HR], 0.36; 95% co

235 A baseline stool Shannon diversity cutoff of <2 had optimal operati

236 e effect of vaccination or prior exposure on stool shedding.

237 s known mechanism of action, which increases stool sodium and water content.

238 ldren with AGE were enrolled and submitted a stool specimen (2187 hospitalized and 4767 in the ED).

239 ctive value (NPV) for the rectal swabs, with stool specimen results being used as the reference stand

240 Each stool specimen was tested for the presence of the tcdB g

241 We utilized remnant stool specimens (n = 79) from 77 patients with gastroint

242 Data on rotavirus-positive stool specimens among children age <5 years hospitalized

243 RT-PCR assays for detection of viral RNA in stool specimens and compared performance.

244 As stool specimens are often collected off-site from the cl

245 ted metabolites were measured by analyses of stool specimens collected at baseline, after preconditio

246 ymptoms or viral nucleic acid clearance from stool specimens collected up to 28 days following enroll

247 From November 2011 to September 2015, stool specimens collected within 7 days of AGE symptom o

248 e Revogene C. difficile test, using clinical stool specimens for detection of tcdB in C. difficile, d

249 Unformed stool specimens from 200 hospitalized adults (100 PCR po

250 Stool specimens from 298 patients with suspected CDI wer

251 years of intervention exposure, we collected stool specimens from 9,077 total children aged 2 to 15 y

252 .17[P17] (GII.17 Kawasaki) strains from case stool specimens matched norovirus found in frozen raspbe

253 d sites that enrolled children and collected stool specimens monthly and tested at least 100 specimen

254 Stool specimens of patients with acute flaccid paralysis

255 ecovered from H type III-coated beads for 13 stool specimens out of 27 SMV-positive specimens tested.

256 identified cases of C. difficile infection (stool specimens positive for C. difficile in a person >=

257 uire transport, we assessed the stability of stool specimens stored for up to 14 days at 4 degrees C,

258 Bulk stool specimens were collected and tested for rotavirus.

259 Stool specimens were collected and tested for Vibrio cho

260 A total of 3705 subjects were enrolled and stool specimens were collected and tested from 2885 (78%

261 A total of 186 unpreserved stool specimens were collected and used to prepare match

262 Stool specimens were tested by RT-qPCR for GI and GII no

263 Stool specimens were tested for 37 infectious agents usi

264 Of 1603 stool specimens, 6% tested were positive for norovirus;

265 ypes were determined from DNA extracted from stool specimens, and frequencies of positive cumulative

266 Four studies reported viral culture from stool specimens.

267 ho completed follow-up and provided multiple stool specimens.

268 subsequently confirmed though genotyping of stool specimens.

269 GF mice were colonized using stools/sterile supernatants.

270 min D metabolites using LC-MSMS and defining stool sub-Operational Taxonomic Units from16S ribosomal

271 symptoms and high levels of viral RNA in the stool suggest active severe acute respiratory syndrome c

272 l study, we performed 16S rRNA sequencing on stool swab samples collected from neonatal intensive car

273 Compositional analyses of 67 stool swab samples demonstrated low diversity and domina

274 7%), while codetection with other viruses in stool swabs was common (64.4%).

275 children age-eligible for >=1 RV1 dose, with stool tested for rotavirus and confirmed vaccination his

276 vestigate all norovirus outbreaks (including stool testing and genotyping), coordinate complaint and

277 guidelines recommend excluding patients from stool testing for C. difficile if they have received lax

278 nd 5,986 patients who underwent conventional stool testing from December 2012 through February 2015.

279 Median total costs of stool testing per patient did not increase (pre: $473; p

280 Median total costs of stool testing per patient did not increase (pre: $473; p

281 HCT recipients after replacing conventional stool testing with a multiplexed PCR assay, without an i

282 Within 14 days following stool testing, patients who received a GI panel were les

283 Laxative use within 48 hours before stool testing, severity of illness (defined by 4 distinc

284 ollowing GI panel compared with conventional stool testing.

285 ur study conducted in 2010-2013, we evaluate stool toxin levels and C. difficile PCR ribotypes.

286 EIA or PCR for the tcdB gene, we quantified stool toxin levels via a modified cell cytotoxicity assa

287 We hypothesized that elevated stool toxins and infection with ribotype 027 associate w

288 at between the 20-mg and 5-mg groups was 0.1 stools (upper boundary of the 98.75% CI, 0.8), both of w

289 e between the 20-mg and 10-mg groups was 0.3 stools (upper boundary of the 98.75% CI, 1.0), and that

290 to a fecal microbiota transplant (FMT) donor stool using multiple growth media, and found significant

291 were measured at days 0, 7, 28, and 56, and stool viral shedding was assessed up to 28 days post-vac

292 the model and scanner using serially diluted stool was 5-fold more sensitive than manual examinations

293 ociated with sulfur-metabolizing bacteria in stool was associated with an increased risk of distal CR

294 RV1 vaccine virus in stool was detected using semiquantitative real-time reve

295 The mean number of diarrheal stools was 10.7 in the 20-mg group, 10.9 in the 10-mg gr

296 In Part 1, LVPEG-3 achieved the largest mean stool weight (3399 g: P < 0.0001 vs target) and was sele

297 or proof of concept demonstration: mean 24-h stool weight and bowel cleansing success (Harefield Clea

298 After euthanization, the serum and stool were collected to perform MS-based quantitative an

299 i-toxin A in blood and IgA/G anti-toxin B in stool were significantly higher in CDI patients compared

300 The stools were sequenced using Earth Microbiome project pro